BRCA1/2 population screening: Embracing the benefits

Current Oncology

Volumn 22, Issue 4, 2015, Pages e230-e231

  Plon, S E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939638227     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2660     Document Type: Editorial

References (16)

1. Richards CS, Ward PA, Roa BB, et al. Screening for 185delAG in the Ashkenazim. Am J Hum Genet 1997;60:1085–98.
2. Plon SE, Peterson LE, Friedman LC, Richards CS. Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study. Genet Med 2000;2:307–11.
3. King MC, Marks JH, Mandell JB on behalf of the New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–6.
4. Levy-Lahad E, Plon SE. Cancer. A risky business—assessing breast cancer risk. Science 2003;302:574–5.
5. Monaghan KG, Feldman GL, Palomaki GE, Spector EB on behalf of the Ashkenazi Jewish Reproductive Screening Working Group and the Molecular Subcommittee of the acmg Laboratory Quality Assurance Committee. Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. Genet Med 2008;10:57–72.
6. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A 2014;111:14205–10.
7. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312:1091–2.
8. Moyer VA on behalf of the U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:271–81.
9. Metcalfe KA, Eisen A, Lerner-Ellis J, Narod SA. Is it time to offer BRCA1 and BRCA2 testing to all Jewish women? Curr Oncol 2015;22:e233-36.
10. Schwartz MD, Valdimarsdottir HB, Peshkin BN, et al. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 2014;32:618–26.
11. Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. J Natl Cancer Inst 2014;107:380.
12. Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst 2014;107:379.
13. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331–7.
14. Jolie A., My medical choice. The New York Times 2013; May 14: A25.
15. Jolie A. Angelina Jolie Pitt: diary of a surgery. The New York Times 2015; March 24: A23.
16. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med 2003;348:50–8.